Dyax (NASDAQ: DYAX) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Dyax to related companies based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, valuation and institutional ownership.

Earnings & Valuation

This table compares Dyax and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Dyax N/A N/A -181.14
Dyax Competitors $290.27 million $35.99 million 59.09

Dyax’s peers have higher revenue and earnings than Dyax. Dyax is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Dyax and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dyax -47.32% -14.86% -12.09%
Dyax Competitors -5,192.50% -162.92% -35.31%

Analyst Ratings

This is a summary of recent ratings for Dyax and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyax 0 0 0 0 N/A
Dyax Competitors 912 3326 11820 237 2.70

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.28%. Given Dyax’s peers higher probable upside, analysts clearly believe Dyax has less favorable growth aspects than its peers.

Institutional & Insider Ownership

49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


Dyax peers beat Dyax on 5 of the 8 factors compared.

About Dyax

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Receive News & Ratings for Dyax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyax and related companies with MarketBeat.com's FREE daily email newsletter.